Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131354 | 0.90 | MAPK8 (0.43) | MAPK8MAPK9MAPK10MAPTKMO | |
| SCHEMBL2807452 | 0.84 | KDM4C (0.38) | MAPK8MAPK9MAPK10RENKDM4E | |
| SCHEMBL2808785 | 0.81 | MAPK8 (0.38) | MAPK8MAPK9MAPK10MAPTNR3C1 | |
| SCHEMBL2807490 | 0.81 | REN (0.49) | RENKDM4EALDH1A1HSD17B10KDM4C | |
| SCHEMBL2810321 | 0.80 | MAPK8 (0.42) | MAPK8MAPK9MAPK10MAPTKMO | |
| SCHEMBL2809620 | 0.78 | ELANE (0.45) | MAPK8MAPK9MAPK10MAPTKMO | |
| SCHEMBL13131355 | 0.74 | KDM4C (0.38) | MAPTRENKDM4EALDH1A1HSD17B10 | |
| SCHEMBL3070090 | 0.71 | REN (0.46) | RENKDM4EALDH1A1HSD17B10KDM4C | |
| SCHEMBL27795791 | 0.71 | MAPT (0.44) | MAPK8MAPTKMOKDM4EKDM4C | |
| SCHEMBL29123059 | 0.70 | ESR1 (0.40) | MAPK8MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | MAPK8 1690/4885MAPK9 1642/4885MAPK10 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.